Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Number of employees : 520 people.
Sales per Businesses
20162017Delta
USD (in Million)%USD (in Million)%
Rare Diseases Treatment Products0.133100%---
Collaboration and License--2.1481.8%-
Product--0.47618.2%-
Sales per Regions
20162017Delta
USD (in Million)%USD (in Million)%
United States0.133100%2.61100% +1863.91%
Managers
NameAgeSinceTitle
Emil D. Kakkis MD, PhD582010President, Chief Executive Officer & Director
Daniel G. Welch, MBA612015Non-Executive Chairman
Wladimir Hogenhuis-2018Chief Operating Officer
Shalini Sharp, MBA442012Chief Financial Officer & Executive Vice President
Dennis Karl Huang542015Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian, MD662018Chief Medical Officer & Executive Vice President
Eric Crombez, MD-2017Chief Medical Officer
Samuel C. Wadsworth, PhD--Chief Scientific Officer-Ultragenyx Gene Therapy
William E. Aliski712011Independent Director
Matthew K. Fust, MBA542014Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 51,278,958 48,025,625 93.7% 0 0.0% 93.7%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 5,856,138 11.6%
Wellington Management Co. LLP 5,274,908 10.4%
Capital Research & Management Co. (International Investors) 4,359,891 8.62%
The Vanguard Group, Inc. 3,951,864 7.81%
BlackRock Fund Advisors 3,546,199 7.01%
Fidelity Management & Research Co. 3,310,512 6.55%
Emil D. Kakkis MD, PhD 3,010,213 5.95%
T. Rowe Price Associates, Inc. 2,778,029 5.49%
SSgA Funds Management, Inc. 1,712,524 3.39%
First Trust Advisors LP 1,471,934 2.91%
Company contact information
Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato, CA 94949

Phone : +1.415.483.8800
Fax : +1.415.483.8810
Web : http://www.ultragenyx.com
Connections : Ultragenyx Pharmaceutical
TB Alliance
Sofinnova Ventures, Inc.
Blackthorn Therapeutics, Inc.
American Society of Nephrology
American Society of Hematology
American Society of Clinical Oncology
Bonti, Inc.
Emil Kakkis & Jenny Soriano Living Trust
Global Alliance for TB Drug Development
Precision BioSciences, Inc.
Dimension Therapeutics, Inc.
Everylife Foundation for Rare Diseases